middle.news
Why Is Opthea Betting Big on OPT-302 for a Rare Lung Disease?
10:23am on Wednesday 17th of December, 2025 AEDT
•
Healthcare
Read Story
Why Is Opthea Betting Big on OPT-302 for a Rare Lung Disease?
10:23am on Wednesday 17th of December, 2025 AEDT
Key Points
Strategic refocus on OPT-302 for LAM, a rare lung disease
Strong IP portfolio with patent protection through 2046
A$37.6 million cash reserves plus R&D tax incentives
Plan to seek orphan drug designation for regulatory and commercial benefits
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Opthea (ASX:OPT)
OPEN ARTICLE